Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

4Total
P 1 (2)
P 2 (2)

Trial Status

Completed1
Active Not Recruiting1
Recruiting1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT04930653Phase 2RecruitingPrimary

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

NCT03011814Phase 1Active Not RecruitingPrimary

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

NCT03380026Phase 2Completed

Mechlorethamine Induced Contact Dermatitis Avoidance Study

NCT03373305Phase 1Withdrawn

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Showing all 4 trials

Research Network

Activity Timeline